Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis

✍ Scribed by Mokenge P. Malafa; Frida D. Fokum; Jennifer Andoh; Leslie T. Neitzel; Sucharita Bandyopadhyay; Rui Zhan; Megumi Iiizumi; Eiji Furuta; Elizabeth Horvath; Kounosuke Watabe

• Book ID: 102269865
• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: French
• Weight: 185 KB
• Volume: 118
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.21689

✦ Synopsis

Abstract

Prostate cancer is a major cause of cancer death and morbidity in western countries. However, because of its intrinsic nature of chemoresistance, there is only limited systemic therapy available for the patients. Vitamin E (VE) has been under intensive study as a chemopreventive agent for various types of cancers. Preclinical studies suggest that vitamin E succinate (VES) is the most effective antitumor analogue of VE, yet there are scarce studies of VES in prostate cancer. In this study, we investigated the effects of VES on a panel of prostate cancer cells, and a xenograft model of prostate cancer. Our results indicate that VES significantly inhibited proliferation and induced apoptosis of prostate cancer cell lines in a dose and time dependent manner. The results of microarray analysis followed by real‐time RT‐PCR and inhibitor analyses indicated that the VES‐induced apoptosis is mediated by caspase‐4 in prostate tumor cells. In our animal model of prostate cancer in SCID mouse, daily injection of VES significantly suppressed tumor growth as well as lung metastases. These results suggest a potential therapeutic utility of VES for patients with prostate cancer. © 2005 Wiley‐Liss, Inc.